3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
2
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Acrocephalosyndactylia
4
Cholangiocarcinoma
2
Carcinoma, Transitional Cell
2
Urinary Bladder Neoplasms
1
Solid Tumor
1
Recurrence
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Myeloproliferative Disorders
1
Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel
1
Eosinophilia
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
341
Paclitaxel
262
Cisplatin
233
Pemetrexed
226
Docetaxel
206
Erlotinib Hydrochloride
193
Gemcitabine
178
pembrolizumab
137
Bevacizumab
121
Radiotherapy
118
Nivolumab
84
Gefitinib
73
Vinorelbine
64
Cetuximab
58
atezolizumab
47
Afatinib
46
durvalumab
44
osimertinib
41
Radiosurgery
35
Ipilimumab
34
Drug Therapy
32
Taxes
30
Albumin-Bound Paclitaxel
29
130-nm albumin-bound paclitaxel
29
Surgical Procedures, Operative
28
Etoposide
25
Irinotecan
24
Sorafenib
21
Cyclophosphamide
20
Radiation
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Non-Small-Cell Lung
×
pemigatinib
×
Clear all
NCT05253807
2025-08-05
FIGHT-210
Incyte Corporation
Phase 2
Completed
8 enrolled
13 charts